drugset / Trial / NCT00605735
PoC in Rheumatoid Arthritis With Methotrexate
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to find out if 300 mg of BMS-582949 given once daily will be more effective than placebo after 12 weeks of treatment in subjects with rheumatoid arthritis who are also taking methotrexate
Timeline
- Start
- 2008-03
- Primary completion
- 2009-08
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-582949 | Small molecule | 300 mg | Oral |